Pharmacology - Salbutamol

Pharmacology - Salbutamol 
The physiological antagonist of spasmogenic mediators is bronchodilatation. Although it has a relatively little impact on the heart, it does have a significant impact on the rate at which the heart beats significantly.

Mode of Action 

At this moment, there is a decrease in the calcium-mediated contraction that occurs in the bronchioles. PKA, which stands for protein kinase A, is activated when there is a rise in cAMP production.
It is the myosin light chain kinase (MLCK) enzyme that is responsible for the mediation of contraction, and PKA is the enzyme that inhibits it.

Clinical Use
By the use of inhalation to treat asthma. The duration of its activity is rather short, ranging from three to five hours, and it can be given intravenously to patients who are experiencing chronic severe asthma.
With the majority of its original shape being removed.

Whenever an acute asthma attack occurs, it is supplied "as needed." This is done in order to prevent asthma attacks that are brought on by physical activity. as a method of treatment for cancer that affects the chronic condition of the airways.

Adverse Effects 
There are a number of symptoms that may be experienced, including unwanted dysrhythmias, tremors, tachycardia, nervousness, and some peripheral dilatation.

When it comes to the immediate phase, which is also referred to as the acute attack, selective beta-2 agonists are the drugs of choice. However, when it comes to the delayed phase, these medications are completely ineffective.